Search results
Results from the WOW.Com Content Network
Bone marrow suppression is a serious side effect of chemotherapy and certain drugs affecting the immune system such as azathioprine. [2] The risk is especially high in cytotoxic chemotherapy for leukemia. In the case of non-small-cell lung cancer, myelosuppression predisposition was shown to be modulated by enhancer mutations. [3]
1.10 Platinum compounds: Carboplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Ovarian cancer, lung cancer and squamous cell head and neck cancer: Myelosuppression, nausea and vomiting (30-90%), peripheral neuropathy, ototoxicity, anaphylaxis, acute kidney failure (rare), haemolytic uraemic syndrome (rare) and loss of ...
Desidustat has been studied for use in conditions beyond anemia of chronic kidney disease, including chemotherapy-induced anemia, inflammation-induced anemia, and acute kidney injury. It is also being evaluated in clinical trials for sickle cell disease and has been suggested as a treatment for complement-mediated diseases and stroke in chronic ...
Azacitidine is a chemical analogue of the nucleoside cytidine, which is present in DNA and RNA.It is thought to have antineoplastic activity via two mechanisms – at low doses, by inhibiting of DNA methyltransferase, causing hypomethylation of DNA, [16] and at high doses, by its direct cytotoxicity to abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA ...
Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology. [1] [2] The term chemotherapy now means the non-specific use of intracellular poisons to inhibit mitosis (cell division) or to induce DNA damage (so that DNA repair can augment chemotherapy ...
284.9 Aplastic anemia unspecified; 285 Other and unspecified anemias. 285.0 Sideroblastic anemia; 285.1 Acute posthemorrhagic anemia; 285.2 Anemia in chronic illness. 285.21 Anemia in chronic kidney disease; 285.22 Anemia in neoplastic disease; 285.29 Anemia of other chronic illness; 285.3 Antineoplastic chemotherapy induced anemia; 285.8 Other ...
Initial symptoms of drug-induced autoimmune hemolytic anemia are typically vague and reflect mild, moderate, or severe anemia. Symptoms of DIIHA can manifest within hours to months of the initial drug exposure. [1] DIIHA ranges in severity from severe intravascular hemolysis to milder presentations of extravascular hemolysis. [7]
Exposure to chemotherapy, in particular alkylating antineoplastic agents, can increase the risk of subsequently developing AML. [9] Other chemotherapy agents, including fludarabine, [9] and topoisomerase II inhibitors are also associated with the development of AML; most commonly after 4–6 years and 1–3 years respectively. [10]